Advertisement
Advertisement
U.S. markets open in 4 hours 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0700-0.0400 (-3.60%)
At close: 04:00PM EDT
1.0700 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement

AVROBIO, Inc.

Building 300
Suite 201 One Kendall Square
Cambridge, MA 02139
United States
617 914 8420
https://www.avrobio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees122

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoff MacKay BScCo- Founder, Pres, CEO & Director754.39kN/A1966
Mr. Erik John Ostrowski M.B.A.CFO & Treasurer554.66kN/A1973
Mr. Jeffrey Medin Ph.D.Scientific FounderN/AN/AN/A
Mr. Matthew ArnoldHead of OperationsN/AN/AN/A
Mr. Steven N. Avruch J.D.Chief Legal Officer & Sec.N/AN/A1961
Ms. Monique Da SilvaSr. VP of Corp. CommunicationsN/AN/AN/A
Ms. Deanna M. Petersen MBAChief Bus. OfficerN/AN/A1962
Ms. Azadeh Golipour Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. Andreas KouriSr. VP of Global Supply Chain & External ManufacturingN/AN/AN/A
Dr. Essra Ridha FFPM, M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

AVROBIO, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement